The risk of cancer progression in women with gynecological malignancies and thrombophilic polymorphisms: A pilot case-control study

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 5, 2009, Pages 535-539

  Tormene, Daniela ^a   Beltramello, Paola ^a   Perlati, Marica ^a   Brandolin, Barbara ^a   Barbar, Sofia ^a   De Toffoli, Giuseppe ^a   Simioni, Paolo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cancer; Factor V Leiden; G20210A prothrombin variant

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; PROTHROMBIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GYNECOLOGIC CANCER; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PILOT STUDY; PRIORITY JOURNAL; THROMBOPHILIA;

ADULT; AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 70449652882     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608317941     Document Type: Article

References (24)

1. Rickles FR, Levine MN Epidemiology of thrombosis in cancer. Acta Haematol. 2001 ; 106: 6-12.
2. Thodiyil PA, Kakkar AK Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002 ; 87: 1076-1077.
3. LÓ;pez JA, Kearon C., Lee AY Deep venous thrombosis. Hematology Am Soc Hematol Educ Program. 2004 ; 1: 439-456.
4. Falanga A., Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005 ; 16: 696-701.
5. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005 ; 6: 401-410.
6. Aderka D., Brown A., Zelikovski A., Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986 ; 57: 1846-1849.
7. Monreal M., Lafoz E., Casals A., et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer. 1991 ; 67: 541-545.
8. Nordstrom M., Lindblad B., Anderson H., Bergqvist D., Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994 ; 308: 891-894.
9. Sorensen HT, Mellemkjaer L., Olsen JH, Baron JA Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000 ; 343: 1846-1850.
10. Morgan MA, Iyengar TD, Napiorkowski BE, Rubin SC, Mikuta JJ The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol. 2002 ; 84: 67-71.
11. Taliani MR, Agnelli G., Prandoni P., et al. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost. 2003 ; 1: 1730-1733.
12. Lee AY Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology Am Soc Hematol Educ Program. 2006 ; 1: 438-443.
13. Fennerty A. Venous thromboembolic disease and cancer. Postgrad Med J. 2006 ; 82: 642-648.
14. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005 ; 31: 104-110.
15. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004 ; 2: 2107-2114.
16. Mandalà M., Curigliano G., Bucciarelli P., et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004 ; 15: 590-593.
17. Kennedy M., Andreescu AC, Greenblatt MS, et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol. 2005 ; 128: 386-388.
18. Blom JW, Doggen CJ, Osanto S., Rosendaal FR Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 ; 293: 715-722. (Pubitemid 40216041)
19. Eroglu A., Ulu A., Cam R., Kurtman C., Akar N. Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis. 2007 ; 23: 31-34.
20. Paspatis GA, Sfyridaki A., Papanikolaou N., et al. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb. 2002 ; 32: 2-7.
21. Pihusch R., Danzl G., Scholz M., et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 2002 ; 94: 3120-3126.
22. Battistelli S., Stefanoni M., Genovese A., Vittoria A., Cappelli R., Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol. 2006 ; 12: 4179-4180.
23. Simioni P., Prandoni P., Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000 ; 96: 3329-3333.
24. Vlodavsky I., Ilan N., Nadir Y., et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res. 2007 ; 120 (suppl 2). 112S - 120S.